Antipsychotic treatment effects and structural MRI brain changes in schizophrenia

Area of Science:

• Neuroimaging
• Psychiatry
• Pharmacology

Background:

• Schizophrenia is associated with progressive brain structural changes.
• These changes are attributed to both illness progression and antipsychotic medication.
• Investigating treatment effects on brain structure is crucial for understanding schizophrenia.

Purpose of the Study:

• To investigate the impact of antipsychotic treatment on brain structural changes over 24 months in schizophrenia patients.
• To examine the relationship between cumulative antipsychotic dose, efficacy, and tolerability with brain structural alterations.
• To differentiate treatment-related changes from illness-related changes in brain structure.

Main Methods:

• Prospective, 24-month, single-site cohort study.
• 99 minimally treated first-episode schizophrenia spectrum patients and 98 healthy controls.
• Long-acting injectable antipsychotic (flupenthixol decanoate) treatment with regular assessments (psychopathology, cognition, EPS, BMI) and MRI scans.

Main Results:

• Patients showed cortical thickness reductions, unrelated to treatment.
• White matter and basal ganglia volumes increased in patients.
• These increases correlated with treatment dose, psychopathology/cognitive improvements, BMI changes, and extrapyramidal symptoms.

Conclusions:

• Evidence suggests white matter and basal ganglia plasticity in schizophrenia associated with antipsychotic treatment, likely via dopamine blockade.
• Cortical changes may be more related to the neurodevelopmental aspects of schizophrenia.
• Findings highlight the complex interplay between medication and brain structure in schizophrenia.